Zylox-tonbridge Medical Technology Co., Ltd. Class H · HKEX:2190
Zylox-tonbridge Medical Technology Co., Ltd. Class H — H1 2022 Earnings Presentation
33 slides from Zylox-tonbridge Medical Technology Co., Ltd. Class H's earnings presentation, August 2022
Slide 1: 2022 Interim Results Presentation
2022 Interim Results Presentation AUGUST 2022
Slide 2: Disclaimer
Disclaimer This presentation has been delivered to interested parties for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above, and it is not intended to form the basis of any investment decision or any decision to purchase
Slide 3: Agenda
Agenda 1 Business Highlights 2 Product and Business Updates 3 Financial Updates 4 Summary 3
Slide 4: Business Highlights
SECTION 1 Business Highlights
Slide 5: Commercialization of High-quality Products Triggered Rapid Revenue Growth
Commercialization of High-quality Products Triggered Rapid Revenue Growth Rapid Revenue Growth in 2022 H1 Sufficient Funds and Efficient Operations (RMB in thousands) (RMB in thousands) GPM： 27.5% 72.9% 75.6% 3,500,000 2,799,870 3,000,000 180,000 160,000 152,743 2,500,000 140,000 2,000,000 41,113 11
Slide 6: Continue to increase penetration through strong sales and distribution network
Continue to increase penetration through strong sales and distribution network Steady Expansion of the Sales & Marketing Extensive Sales Network Team Supports the Rapid Development 127 Northernmost Heihe 93 50 Westernmost Easternmost Kashi Shuangyashan 2021.6.30 2021.12.31 2022.6.30 Highest
Slide 7: Efficient R&D Lays a Solid Foundation for Continuous Growth
Efficient R&D Lays a Solid Foundation for Continuous Growth R&D Progress as of August 15,2022 R&D Pipelines Progressed Efficiently Development Status Products in China Type Design Clinical Approval testing Carotid Rx PTA 1 Balloon Approved in March 2022 Catheter (Rx) Carotid Rx PTA Balloon Endovenou
Slide 8: In-house R&D Technology Platforms Solidify the Competitive Advantages
In-house R&D Technology Platforms Solidify the Competitive Advantages Expertise in fundamental technology know-how cross different disciplines enables rapid prototyping and expedites the transformation of prototypes to ready-to-commercialize products with consistent high quality and efficiency Ballo
Slide 9: In-house R&D Technology Platforms Solidify the Competitive Advantages (Con'd)
In-house R&D Technology Platforms Solidify the Competitive Advantages (Con’d) Expertise in fundamental technology know-how cross different disciplines enables rapid prototyping and expedites the transformation of prototypes to ready-to-commercialize products with consistent high quality and efficien
Slide 10: Product and Business Updates
SECTION 2 Product and Business Updates
Slide 11: Robust R&D Pipelines Bolster the Long-term Growth
Robust R&D Pipelines Bolster the Long-term Growth Expect to launch 55 products in 26 27 2 total domestically in the Neurovascular Peripheral-vascular Vascular Closure upcoming 4 years Interventional Products Interventional Products Devices Category As of August 15, 2022 Before the end of 2022 2023 2
Slide 12: Products Update - Neurovascular Interventional Portfolio
Products Update - Neurovascular Interventional Portfolio Intracranial Intracranial Intracranial Diseases Hemorrhagic Ischemic Stroke Stenosis Stroke Volume of Ischemic Stroke Treatment Volume of Intracranial Aneurysms Intervention Volume of Intracranial Stenosis Procedures in China Procedures in Chi
Slide 13: Neurovascular - Rapid Revenue Growth
Neurovascular - Rapid Revenue Growth Revenue of Neurovascular Products Top Products by Sales （(RMB in thousands) % of Revenue: 0.7% 60.0% 73.1% Clot Retriever 120,000 111,630 Device 100,000 Intracranial 80,000 160% Balloon Catheter(Rx) 60,000 42,912 40,000 Intracranial Support 20,000 Catheter 15 0 2
Slide 14: Professional Academic Marketing Strategy – Neurovascular Interventional Portfolio
Professional Academic Marketing Strategy – Neurovascular Interventional Portfolio Online – Highly Frequent and Deep Communication with KOLs In-depth case studies newsletter： • H1 published 44 cases（7+ cases / month）; • Covered ischemic \ hemorrhagic \ intracranial stenosis topics and products; • Foc
Slide 15: Professional Academic Marketing Strategy – Neurovascular Interventional Portfolio (Con'd)
Professional Academic Marketing Strategy – Neurovascular Interventional Portfolio （Con’d） Offline—— High-quality flagship events • BADDASS training courses are in full swing: In the first half of 2022, we have covered 3 Large Stroke Centers in Zhengzhou, Zhangzhou and Dalian to further promote BADDA
Slide 16: Neurovascular – Key Products Expected to be Launched within the Next Three Years
Neurovascular – Key Products Expected to be Launched within the Next Three Years Aspiration Second Generation Flow Diverter Catheter Clot Retriever Device Effects: Effects: Effects: • Expected to be used for the treatment • Expected to be used for the treatment of wide- • Expected to be used for of
Slide 17: Products Update - Peripheral-vascular Interventional Portfolio
Products Update - Peripheral-vascular Interventional Portfolio Hemodialysis Diseases Arterial Venous Access • UItraFree® Drug Coated PTA • Snare Retrieval Kit for IVC Filter / • High Pressure PTA Balloon Balloon Catheter/ Launched Launched Catheter / Launched • Second Generation UItraFree® • Endovas
Slide 18: Peripheral Vascular Intervention Medical Devices Market Overview
Peripheral Vascular Intervention Medical Devices Market Overview Peripheral Arterial Disease Peripheral Venous Disease Intervention Market Overview (1) Intervention Market Overview (1) Historical and Forecasted Volume of Peripheral Artery Historical and Forecasted Volume of IVCF Intervention Interve
Slide 19: Peripheral-vascular - Steady Revenue Growth
Peripheral-vascular - Steady Revenue Growth Revenue of Peripheral-vascular Products Top Products by Sales (RMB in thousands) % of 99.3% 40.0% 26.9% Revenue: 45,000 41,113 40,000 44% 35,000 30,000 28,572 Drug Coated PTA High Pressure PTA 25,000 Balloon Catheter Balloon Catheter 20,000 15,000 10,000 5
Slide 20: Professional Academic Marketing Strategy – Peripheral Vascular Interventional Portfolio
Professional Academic Marketing Strategy – Peripheral Vascular Interventional Portfolio Active Participation in Professional Zylox Institute Widely Serve Healthcare Academic Conferences Professionals 「 Tan’Suo Kai’Tuo(探索•开拓)」 Zylox –Tonbridge @ The 7th Vascular Innovation Conference Zylox Institute「
Slide 21: Peripheral – Key Products Expected to be Launched within the next three years
Peripheral – Key Products Expected to be Launched within the next three years Peripheral Venous Stent System Technical Features Clinical study updates Before After implantation After dilated implantation Patient enrollment completed in 10 months for the PEVENSEY study Lumen patency rate patients
Slide 22: Peripheral – Key Products Expected to be Launched within the next three years
Peripheral – Key Products Expected to be Launched within the next three years Suture-mediated Closure System Product Structure Industry Overview(1) Historical and Forecasted Volume of Vascular Closure Suture-mediated closure device Procedures in China， 2015-2030E 3,782.1 Unit: Thousand Closure of ar
Slide 23: Financial Highlights
SECTION 3 Financial Highlights
Slide 24: Rapid Growth Driven by Successful R&D and Commercialization
Rapid Growth Driven by Successful R&D and Commercialization GPM Improves with Sales Optimization Rapid Revenue Growth in 2022 H1 and Scale Effect (RMB in thousands) (RMB in thousands) GPM： 27.5% 72.9% 75.6% 180,000 180,000 160,000 152,743 160,000 140,000 140,000 114% 41,113 120,000 120,000 122% 115,
Slide 25: Increasing Operating Expenses Level in Line with Development
Increasing Operating Expenses Level in Line with Development Selling and Distribution Expenses R&D Expenses Administrative Expenses (RMB in thousands) (RMB in thousands) (RMB in thousands) % of Revenue(1) 231% 29% 30% 1,288% 55% 49% 318% 30% 27% 100,000 94,039 90,000 80,000 70,000 60,000 54,164 53,3
Slide 26: Sufficient Cash and Efficient Operations to Support Rapid Growth in the Coming Years
Sufficient Cash and Efficient Operations to Support Rapid Growth in the Coming Years Other Non-operating Income and Expenses Adjusted Net Profit / (Loss) (RMB in thousands) (RMB in thousands) 2020H1 2021H1 2022H1 2020H1 2021H1 2022H1 70,000 10,000 8,641 60,000 0 3,648 50,000 (10,000) (21,409) 16,153
Slide 27: Sufficient Cash and Efficient Operations to Support Rapid Growth in the Coming Years
Sufficient Cash and Efficient Operations to Support Rapid Growth in the Coming Years 2022 H1 Cash Movement Accounts Receivable Turnover Accounts Payable Turnover (RMB in thousands) (Turnover Days) (Turnover Days) 3,500,000 360 360 338 2,928,87 330 330 4 2,799,87 3,000,000 0 300 300 270 270 2,500,000
Slide 28: Summary
SECTION 4 D sabi — etn ZYLOX-TONBRIDGE
Slide 29: Summary
Summary 1 The Most Comprehensive Product Portfolio in China - Provide full suite solutions for doctors and patients - Diversified product portfolio to reduce product revenue concentration - Attract high-quality dealers and enhance competitive advantage 2 Strong In-house R&D Capabilities - Dedicated
Slide 30: Thank You!
Thank You!
Slide 31: Appendix
Appendix Please refer to the 2022 Interim Results Announcement for further information Click to download the 2022 Interim Results Announcement
Slide 32: Interim Condensed Consolidated Statement of Comprehensive Loss
Interim Condensed Consolidated Statement of Comprehensive Loss Year ended December 31, Six months ended June 30, RMB’000 (unaudited) % of % of % of % of 2020 Revenue 2021 Revenue 2021 Revenue 2022 Revenue Revenue 27,631 100% 177,912 100% 71,484 100% 152,743 100% Cost of sales (11,344) -41% (46,031)
Slide 33: Interim Condensed Consolidated Balance Sheet
Interim Condensed Consolidated Balance Sheet As at RMB’000 December 31, 2021 June 30, 2022 Non-current assets Property, plant and equipment 178,270 211,549 Right-of-use assets 34,115 35,996 Intangible assets 4,889 4,041 Prepayments 6,804 25,997 Total non-current assets 224,078 277,583 Current assets
Zylox-Tonbridge Medical Technology — H1 2022 Earnings Presentation on 6ix